Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
NDC Package Code : 83703-564
Start Marketing Date : 2011-08-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (50.5mg/10.5mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Vinblastine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, Large-Cell, Anaplastic.
Lead Product(s): Vinblastine Sulfate,Brentuximab Vedotin,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: University of Alabama at Birmingham | Helen DeVos Children's Hospital | Nationwide Children’s Hospital | Memorial Sloan Kettering Cancer Center | University of Utah | Ohio State University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2025
Lead Product(s) : Vinblastine Sulfate,Brentuximab Vedotin,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : University of Alabama at Birmingham | Helen DeVos Children's Hospital | Nationwide Children’s Hospital | Memorial Sloan Kettering Cancer Center | University of Utah | Ohio State University
Deal Size : Inapplicable
Deal Type : Inapplicable
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Details : Vinblastine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, Large-Cell, Anaplastic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2025
Details:
Adcetris (brentuximab vedotin) is a CD30 inhibitor, is now approved in combination with lenalidomide and rituximab for the treatment of Stage IIb/III/IV hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Cyclophosphamide,Dacarbazine
Therapeutic Area: Oncology Brand Name: Adcetris
Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2025
Lead Product(s) : Brentuximab Vedotin,Cyclophosphamide,Dacarbazine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Approves ADCETRIS® (brentuximab vedotin) in Combination with ECADD
Details : Adcetris (brentuximab vedotin) is a CD30 inhibitor, is now approved in combination with lenalidomide and rituximab for the treatment of Stage IIb/III/IV hodgkin lymphoma.
Product Name : Adcetris
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
June 03, 2025
Details:
Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hodgkin Disease.
Lead Product(s): Brentuximab Vedotin,Etoposide,Cyclophosphamide,Doxorubicin Hydrochloride,Dacarbazine,Dexamethasone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2025
Lead Product(s) : Brentuximab Vedotin,Etoposide,Cyclophosphamide,Doxorubicin Hydrochloride,Dacarbazine,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
Details : Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
June 03, 2025
Details:
Summit will provide AK112/SMT112 (ivonescimab), a novel global first-in-class PD-1/VEGF bi-specific immunotherapy, in combination with several of Pfizer's ADCs.
Lead Product(s): Ivonescimab,Brentuximab Vedotin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Antibody, Unconjugated
Sponsor: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 24, 2025
Lead Product(s) : Ivonescimab,Brentuximab Vedotin
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Summit and Pfizer Collaborates to Explore Ivonescimab in Combination with Pfizer's ADCs
Details : Summit will provide AK112/SMT112 (ivonescimab), a novel global first-in-class PD-1/VEGF bi-specific immunotherapy, in combination with several of Pfizer's ADCs.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 24, 2025
Details:
Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hodgkin Disease.
Lead Product(s): Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate,Dacarbazine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 18, 2025
Lead Product(s) : Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate,Dacarbazine
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 18, 2025
Details:
Adcetris (brentuximab vedotin) is a CD30 inhibitor, is now approved in combination with lenalidomide and rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Lead Product(s): Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area: Oncology Brand Name: Adcetris
Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2025
Lead Product(s) : Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Pfizer’s ADCETRIS Combo for Relapsed/Refractory DLBCL
Details : Adcetris (brentuximab vedotin) is a CD30 inhibitor, is now approved in combination with lenalidomide and rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Product Name : Adcetris
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
February 12, 2025
Details:
Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hodgkin Disease.
Lead Product(s): Brentuximab Vedotin,Doxorubicin Hydrochloride,Etoposide,Prednisone,Cyclophosphamide,Dacarbazine,Tislelizumab,Bendamustine Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody-drug Conjugate
Sponsor: Shanghai Children's Medical Center | Najing Children's Hospital | West China Second University Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Institute and Hospital | Tongji Hospital | Xiangya Hospital, Central South U
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 20, 2024
Lead Product(s) : Brentuximab Vedotin,Doxorubicin Hydrochloride,Etoposide,Prednisone,Cyclophosphamide,Dacarbazine,Tislelizumab,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Shanghai Children's Medical Center | Najing Children's Hospital | West China Second University Hospital | Qilu Hospital of Shandong University | Tianjin Medical University Cancer Institute and Hospital | Tongji Hospital | Xiangya Hospital, Central South U
Deal Size : Inapplicable
Deal Type : Inapplicable
Brentuximab Vedotin for Newly Diagnosed CHL in Chinese CAYA Based on PET/CT Assessment
Details : Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 20, 2024
Details:
Adcetris (brentuximab vedotin) is a CD30 inhibitor, which is being evaluated in combination with lenalidomide and rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Lead Product(s): Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area: Oncology Brand Name: Adcetris
Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 01, 2024
Lead Product(s) : Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ADCETRIS® Shows Improvement in Overall Survival in Relapsed DLBCL Patients
Details : Adcetris (brentuximab vedotin) is a CD30 inhibitor, which is being evaluated in combination with lenalidomide and rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Product Name : Adcetris
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
June 01, 2024
Details:
Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.
Lead Product(s): Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate,Dacarbazine,Pembrolizumab,Gemcitabine,Vinorelbine Tartrate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2024
Lead Product(s) : Brentuximab Vedotin,Doxorubicin Hydrochloride,Vinblastine Sulfate,Dacarbazine,Pembrolizumab,Gemcitabine,Vinorelbine Tartrate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Details : Brentuximab Vedotin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 22, 2024
Details:
Pfizer's Adcetris (brentuximab vedotin), a CD30 inhibitor, is in Phase III clinical trials with Lenalidomide and Rituximab for relapsed/refractory diffuse large B-cell lymphoma treatment.
Lead Product(s): Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area: Oncology Brand Name: Adcetris
Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2024
Lead Product(s) : Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pfizer Reports Positive Overall Survival in Phase 3 Trial Of ADCETRIS® for DLBCL
Details : Pfizer's Adcetris (brentuximab vedotin), a CD30 inhibitor, is in Phase III clinical trials with Lenalidomide and Rituximab for relapsed/refractory diffuse large B-cell lymphoma treatment.
Product Name : Adcetris
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 12, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : USA
Brand Name : ADCETRIS
Dosage Form : INJECTABLE; INJECTION
Dosage Strength : 50MG/VIAL
Packaging :
Approval Date :
Application Number : 125388
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : ADCETRIS
Dosage Form : INJECTABLE; INJECTION
Dosage Strength : 50MG/VIAL
Packaging :
Approval Date :
Application Number : 125399
Regulatory Info :
Registration Country : USA
Regulatory Info : Schedule D
Registration Country : Canada
Brand Name : ADCETRIS
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 50MG/VIAL
Packaging :
Approval Date :
Application Number : 2401347
Regulatory Info : Schedule D
Registration Country : Canada
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Adcetris
Dosage Form : Powder For Concentrate For Solution For Infusion
Dosage Strength : 50mg
Packaging :
Approval Date : 25/10/2012
Application Number : 20110707000020
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Adcetris
Dosage Form : Powder For Concentrate For Solution For Infusion
Dosage Strength : 50mg
Packaging :
Approval Date : 04/03/2013
Application Number : 62132
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Adcetris
Dosage Form : Powder For Concentrate For Infusion Solution
Dosage Strength : 50MG
Packaging :
Approval Date : 2012-11-29
Application Number : 112794001
Regulatory Info : Authorized
Registration Country : Spain
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Adcetris
Dosage Form : Powder For Concentrate For Infusion Solution
Dosage Strength : 50MG
Packaging :
Approval Date : 2021-01-08
Application Number : 112794001IP
Regulatory Info : Authorized
Registration Country : Spain
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Adcetris
Dosage Form : INF
Dosage Strength : 50mg
Packaging : 10X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Australia
Brand Name : Adcetris
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Adcetris
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
